B7x and its derivatives for treating and preventing cardiovascular disease

Patent metadata

Field	Value
Publication number	US-2016304581-A1
Application number	US-201415100995-A
Country	US
Kind code	A1
Filing date	Dec 9, 2014
Priority date	Dec 18, 2013
Publication date	Oct 20, 2016
Grant date	—

Abstract

Methods are disclosed for preventing and/or treating cardiovascular diseases comprising administering B7x or a derivative of B7x to a patient in need thereof.

First claim

1 . A method of preventing a cardiovascular disease in a patient at risk for developing a cardiovascular disease and/or for treating a cardiovascular disease in a patient in need thereof comprising administering to the patient B7x or a B7x derivative in an amount effective to prevent and/or treat a cardiovascular disease in a patient.

2 . The method of claim 1 , wherein B7x is administered to the patient.

3 . The method of claim 1 , wherein a B7x derivative is administered to the patient.

4 . The method of claim 3 , wherein the B7x derivative is a B7x Ig fusion protein.

5 . The method of claim 4 , a coding region of the extracellular domain of B7x is fused to a human IgG1 fragment crystallizable region (Fc region).

6 . The method of claim 1 , wherein the patient has a cardiovascular disease.

7 . The method of claim 1 , wherein the patient is at risk for developing a cardiovascular disease.

8 . A method of screening for a compound that treats and/or prevents a cardiovascular disease in a patient, the method comprising
determining whether or not a B7x derivative binds to a receptor on T cells, wherein a B7x derivative that binds to a receptor on T cells is a candidate compound for treating and/or preventing a cardiovascular disease, and testing the candidate compound to determine whether or not the candidate compound treats and/or prevents a cardiovascular disease.

9 . A method for screening for a compound that treats and/or prevents a cardiovascular disease in a patient, the method comprising
obtaining a derivative of B7x, and testing whether or not the B7x derivative treats and/or prevents a cardiovascular disease.

10 . The method of claim 1 , wherein the cardiovascular disease is atherosclerosis, coronary heart disease, carotid artery disease, peripheral arterial disease, or chronic kidney disease.

11 . The method of claim 1 , wherein the patient is a human.

Assignees

• Albert Einstein College Of Medicene Inc
• Albert Einstein College Medicine Inc

Inventors

• Zang Xingxing
• Jeon Hyungjun

Classifications

• G01N33/566

  using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds} · CPC title

• G01N33/56972

  White blood cells · CPC title

• C07K14/70532 Primary

  B7 molecules, e.g. CD80, CD86 · CPC title

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• G01N2333/705

  Assays involving receptors, cell surface antigens or cell surface determinants · CPC title